Area of property subleased.

No definition available.

Name:	crvs_AreaOfPropertySubleased
Namespace Prefix:	crvs_
Data Type:	dtr-types:areaItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of clinical trial expense incurred during the period.

+ References

No definition available.

+ Details

Name:	crvs_ClinicalTrialExpense
Namespace Prefix:	crvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of internal personnel costs billed to related party during the period.

+ References

No definition available.

+ Details

Name:	crvs_RelatedPartyInternalPersonnelCosts
Namespace Prefix:	crvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

n/a

+ References

No definition available.

+ Details

Name:	crvs_RelatedPartyStockTransactionsAbstract
Namespace Prefix:	crvs_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of third party costs billed to related party during the period.

+ References

No definition available.

+ Details

Name:	crvs_RelatedPartyThirdPartyCosts
Namespace Prefix:	crvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Aggregate value of stock issued to related parties in public offerings.

+ References

No definition available.

+ Details

Name:	crvs_StockIssuedRelatedPartyAggregateValue
Namespace Prefix:	crvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of sublease income in connection with related party transactions.

+ References

No definition available.

+ Details

Name:	crvs_SubleaseIncomeRelatedParty
Namespace Prefix:	crvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- References

No definition available.

+ Details

Name:	us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=crvs_AngelPharmaceuticalsCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=crvs_IconPlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=crvs_FollowOnPublicOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=crvs_OrbimedAdvisorsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=crvs_AngelPharmaceuticalsCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party Transactions (Details)		1 Months Ended			3 Months Ended		9 Months Ended
Related Party Transactions (Details)	Apr. 26, 2016 $ / shares shares	Aug. 31, 2021 ft²	Feb. 28, 2021 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021
Public Offerings
Proceeds from sale of stock								$ 31,989,000
Owners of More Than 5% of Our Common Stock or Board of Directors
Area of property subleased \| ft²		7,585
Sublease income - related party					$ 147,000	$ 94,000	$ 439,000	94,000
Angel Pharmaceuticals
Owners of More Than 5% of Our Common Stock or Board of Directors
Area of property subleased \| ft²		7,585
Sublease income - related party					$ 146,000		440,000
ICON plc
Owners of More Than 5% of Our Common Stock or Board of Directors
Clinical trial expense							$ 330,000	205,000
Follow On Public Offering
Public Offerings
Issuance of common stock (in shares) \| shares			9,783,660	8,117,647
Share offering price \| $ / shares			$ 3.50	$ 8.50
Proceeds from sale of stock			$ 32,000,000.0	$ 64,900,000
Follow On Public Offering \| Orbimed Advisors LLC
Public Offerings
Issuance of common stock (in shares) \| shares			1,285,714
Owners of More Than 5% of Our Common Stock or Board of Directors
Aggregate Purchase Price			$ 4,499,999
Follow On Public Offering \| Richard A. Miller, M.D.
Public Offerings
Issuance of common stock (in shares) \| shares			100,000
Owners of More Than 5% of Our Common Stock or Board of Directors
Aggregate Purchase Price			$ 350,000
Over-Allotment Option
Public Offerings
Issuance of common stock (in shares) \| shares	502,618		1,212,231	1,058,823
Share offering price \| $ / shares	$ 15.00
Angel Pharmaceuticals
Related Party Transactions
Ownership interest (as percent)					49.70%		49.70%		49.70%
Angel Pharmaceuticals \| Angel Pharmaceuticals
Related Party Transactions
Ownership interest (as percent)									49.70%
Owners of More Than 5% of Our Common Stock or Board of Directors
Internal personnel costs							$ 140,000	167,000
Third-party costs							$ 631,000	$ 470,000